Last reviewed · How we verify
JNJ-54861911, 50 mg
JNJ-54861911, 50 mg is a Small molecule drug developed by Janssen Pharmaceutical K.K.. It is currently in Phase 2 development.
At a glance
| Generic name | JNJ-54861911, 50 mg |
|---|---|
| Sponsor | Janssen Pharmaceutical K.K. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease (PHASE2)
- Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia (PHASE1)
- A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates (PHASE1)
- A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease (PHASE1)
- A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants (PHASE1)
- A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JNJ-54861911, 50 mg CI brief — competitive landscape report
- JNJ-54861911, 50 mg updates RSS · CI watch RSS
- Janssen Pharmaceutical K.K. portfolio CI
Frequently asked questions about JNJ-54861911, 50 mg
What is JNJ-54861911, 50 mg?
JNJ-54861911, 50 mg is a Small molecule drug developed by Janssen Pharmaceutical K.K..
Who makes JNJ-54861911, 50 mg?
JNJ-54861911, 50 mg is developed by Janssen Pharmaceutical K.K. (see full Janssen Pharmaceutical K.K. pipeline at /company/janssen-pharmaceutical-k-k).
What development phase is JNJ-54861911, 50 mg in?
JNJ-54861911, 50 mg is in Phase 2.
Related
- Manufacturer: Janssen Pharmaceutical K.K. — full pipeline
- Compare: JNJ-54861911, 50 mg vs similar drugs
- Pricing: JNJ-54861911, 50 mg cost, discount & access